Get started
Author

Deniz Işık

Observed names: D. Isik, D. Isık, DENİZ IŞIK, Deniz ISIK, Deniz Isik, Deniz Isık, Deniz IŞIK, Deniz Işik
ORCID: 0000-0003-4398-5148
Observed ORCIDs: 0000-0003-4398-5148, 0000-0002-1457-3489
OpenAlex ID: A5079748237
The role of laboratory indices on treatment response and survival in breast cancer receiving neoadjuvant chemotherapy
2024 · Sedat Yildirim, Akif Dogan, et al. · Scientific Reports · 28
Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer
2023 · Seda Kahraman, Enes Erul, et al. · Future Oncology · 27
Evaluation of Bevacizumab in Advanced Small Bowel Adenocarcinoma
2016 · Dincer Aydin, Mehmet Ali Sendur, et al. · Clinical Colorectal Cancer · 27
Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy
2023 · Cengiz Karacin, Berna Oksuzoglu, et al. · BMC Cancer · 23
PDF
Treatment outcomes and prognostic factors in patients with driver mutant non-small cell lung cancer and de novo brain metastases
2024 · Seda Kahraman, Serdar Karakaya, et al. · Scientific Reports · 18
Efficacy and Safety of Trastuzumab Emtansine in Her2 Positive Metastatic Breast Cancer: Real-World Experience
2021 · Aykut Bahçeci, Semra Paydaş, et al. · Cancer Investigation · 17
Comparison of efficacy and safety of three different chemotherapy regimens delivered with concomitant radiotherapy in inoperable stage III non-small cell lung cancer patients
2016 · Melike Ozcelik, Taner Korkmaz, et al. · Tumor Biology · 16
Tumor-infiltrating lymphocytes as predictive biomarkers in neoadjuvant treatment of HER2-positive breast cancer
2025 · Oğuzcan Kınıkoğlu, Yunus Emre Altıntaş, et al. · The Oncologist · 11
Prognostic Impact and Clinical Features of Spread through Air Spaces in Operated Lung Cancer: Real-World Analysis
2024 · Sedat Yildirim, Ozkan Alan, et al. · Medicina · 11
PDF
Evaluating the Performance of ChatGPT-4o Oncology Expert in Comparison to Standard Medical Oncology Knowledge: A Focus on Treatment-Related Clinical Questions
2025 · Oguzcan Kinikoglu, Deniz Isik · Cureus · 9
PDF
Neoadjuvant Chemotherapy and Pathologic Complete Response in HR+/HER2− Breast Cancer: Impact of Tumor Ki67 and ER Status
2024 · Goncagul Akdag, Sedat Yildirim, et al. · Chemotherapy · 9
A Novel Prognostic Indicator for Immunotherapy Response: Lymphocyte-to-Albumin (LA) Ratio Predicts Survival in Metastatic NSCLC Patients
2024 · Sedat Yildirim, Akif Dogan, et al. · Cancers · 8
Triple-Negative Apocrine Carcinoma: Largest Cohort Highlights Unique Biology and Survival Advantage
2025 · Tugba Basoglu, Ugur Ozkerim, et al. · Journal of Clinical Medicine · 6
PDF
The Association of Khorana Risk Score with Venous Thromboembolism and Overall Survival in Patients with Metastatic Gastric Cancer
2025 · Ezgi Turkoglu, Goncagul Akdag Topal, et al. · Medicina · 6
PDF
Activity of CDK4/6 inhibitors and parameters affecting survival in elderly patients in age-subgroups: Turkish Oncology Group (TOG) retrospective study
2024 · Seda Kahraman, Mutlu Hizal, et al. · BMC Cancer · 6
PDF
Real-World Treatment Efficacy of Ribociclib or Palbociclib Plus Fulvestrant in Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study
2025 · Seda Kahraman, Enes Erul, et al. · Clinical Breast Cancer · 5
Correction: Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy
2023 · Cengiz Karacin, Berna Oksuzoglu, et al. · BMC Cancer · 5
PDF
Association between GRIm score and response to nivolumab monotherapy in patients with advanced malignant melanoma
2026 · Sila Oksuz, Oguzcan Kinikoglu, et al. · Journal of Cancer Research and Clinical Oncology · 4
PDF
Development of a Machine Learning-Based Prognostic Model Using Systemic Inflammation Markers in Patients Receiving Nivolumab Immunotherapy: A Real-World Cohort Study
2025 · Ugur Ozkerim, Deniz Isik, et al. · Journal of Personalized Medicine · 4
PDF
Does Adjuvant Chemotherapy Benefit Patients with T4 N0 Colon Cancer?
2024 · Goncagul Akdag, Deniz Isik, et al. · Medicina · 4
PDF
Association Between Time to PSA Nadir, Radiologic Progression, and PSA Progression in mHSPC Patients Treated with Abiraterone or Enzalutamide
2026 · Ugur Ozkerim, Oguzcan Kinikoglu, et al. · Journal of Clinical Medicine · 3
PDF
Efficacy and Clinical Outcomes of Crizotinib in Patients with ROS1-Rearranged NSCLC: A Multicenter Study
2025 · Alper Topal, Goncagul Akdag, et al. · Medicina · 3
Evaluating the Effectiveness of Nivolumab in Metastatic Lung Cancer Among Patients Aged 65 and Older
2024 · Deniz ISIK, Özkan Alan, et al. · Journal of Clinical Medicine · 3
PDF
Impact of Peri-Immunotherapy Antibiotic Exposure on Survival Outcomes in Metastatic Renal Cell Carcinoma: A Real-World IMDC Risk–Stratified Analysis
2026 · Sila Oksuz, Oguzcan Kinikoglu, et al. · Journal of Clinical Medicine · 2
PDF
Prognostic Impact of Tumor Size in Patients with Stage T3N1 Colon Cancer
2025 · Ezgi Turkoglu, Nisanur Sarıyar Busery, et al. · Journal of Clinical Medicine · 2
PDF
Works count: 70
Citation count: 286
H-index: 9
I10-index: 9
Year
Topic
Type